Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine

Table 3 HBV genotypes, variants, and lamivudine-resistant mutants

Patients with VBT				During BT
Patient	Sex	BT	Genotype	Month after LAM	ALT	HBeAg	HBV DNA log10 copies/mL	PC	CP A1763T G1765A	L180M	M204I/V
1	F	+	C	19	90	-	5.4	Wild	TA	M	I/V
2	M	+	C	18	29	-	3	Stop	TA	L	I/V
3	F	+	C	12	12	+	6.8	Wild	AG	L	M
4	M	+	C	18	44	+	8.3	Wild	TA	M	I/V
5	M	+	C	36	NA	+	5.2	Wild	TA	M	I/V
6	F	+	C	21	42	+	5.7	Wild	AG	L	M
7	M	+	C	27	24	+	6.6	Stop	TA	M	I/V
8	F	+	C	21	NA	+	6.7	Wild	AG	L	M
9	F	+	C	30	108	+	6.7	Wild	TA	M	I/V
Patients without VBT				End of follow-up
Patient	Sex	BT	Genotype	Month after LAM	ALT	HBeAg	HBV DNA log10 copies/mL	PC	CP A1763T G1765A	L180M	M204I/V
1	M	-	C	9	28	+	4.6	Wild	TA	L	M
2	M	-	C	30	NA	+	5.4	Wild	TA	L	M
3	M	-	C	32	12	-	1	UD	UD	L	M
4	M	-	C	27	NA	+	1	Wild	TA	L	M
5	M	-	C	36	42	-	1	UD	UD	L	M
6	M	-	C	24	24	+	1	Wild	TA	UD	UD

PC: Precore mutants; CP: Core promotor mutants; SR: Suboptimal response; NA: Not available; UD: Undetectable; LAM: Lamivudine; BT: Breakthrough; VBT: Virologic breakthrough.